Monitoring of bone marrow minimal residual disease combined with genetic analysis identifies different risk groups in stage M neuroblastoma patients - Riegler, S; Ambros, IM; Pötschger, U; Mann, G; Ziegler, A; Modritz, D; Crazzolara, R; Ussowicz, M; Benesch, M; Ebetsberger-Dachs, G; Schleiermacher, G; Chan, GC; Jones, N; Yaniv, I; Balwierz, W; Holter, W; Ladenstein, R; Ambros, PF (Klinische Pädiatrie, 2017)